About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Focal treatment-resistant epilepsy ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly ...

The new study, part of the international Human Epilepsy Project, tracked nearly 150 adults who were deemed ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

Neurologist Dr. Kenichiro Ono discusses deep brain stimulation and treating epilepsy. Neurologist Dr. Kenichiro Ono talks about collaborating with researchers at Virginia Commonwealth University that ...

Early detection of focal epilepsy may reduce the amount of motor vehicle accidents caused by seizures while driving. The prevalence of seizures while driving (SzWD) prior to diagnosis in people with ...

Transdermal CBD was well tolerated and safe among those with drug-resistant focal epilepsy, although no efficacy was observed compared with placebo during a 12-week treatment period, researchers ...

Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...